Personnel Information

写真a

TSUJI Kohei


Job title

Associate Professor

Laboratory Address

2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

Mail Address

The inquiry by e-mail is 《here

Homepage URL

http://tamamura-tmd.sakura.ne.jp/

Research Areas, Keywords

peptide, Medicinal Chemistry, Chemical Biology, Organic Chemistry

Graduating School 【 display / non-display

  • The University of Tokushima, Faculty of Pharmaceutical Science, 2010.03, Graduated

Graduate School 【 display / non-display

  • The University of Tokushima, Master's Course, 2012.03, Completed

  • The University of Tokushima, Doctor's Course, 2015.09, Completed

Campus Career 【 display / non-display

  • 2019.09
    -
    2021.12
    Tokyo Medical and Dental University, Institute of Biomaterials and Bioengineering, Biomolecular Chemistry, Medicinal Chemistry, Assistant Professor
  • 2022.01
    -
    2023.03
    Tokyo Medical and Dental University, Institute of Biomaterials and Bioengineering, Biomolecular Chemistry, Medicinal Chemistry, Associate Professor
  • 2023.04
    -
    Now
    Tokyo Medical and Dental University, Institute of Biomaterials and Bioengineering, -, Medicinal Chemistry, Associate Professor

External Career 【 display / non-display

  • 2015.10
    -
    2019.08
    National Institutes of Health, National Cancer Institutes, Visiting Fellow
  • 2017.01
    -
    2018.12
    JSPS Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH, JSPS Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH

Academic Society Affiliations 【 display / non-display

  • The Pharmaceutical Society of Japan

  • The Japanese Peptide Society

  • American Chemical Society

  • American Peptide Society

Research Areas 【 display / non-display

  • Chemical biology

  • Pharmaceutical chemistry and drug development sciences

Qualification Acquired 【 display / non-display

  • Pharmacist

 

Published Papers & Misc 【 display / non-display

  1. Kobayakawa T, Tsuji K, Tamamura H. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres. Bioorganic & medicinal chemistry. 2024.08; 110 117811. ( PubMed, DOI )

  2. Tsuji K, Tamamura H, Burke TR Jr. Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. RSC chemical biology. 2024.07; 5 (8): 721-728. ( PubMed, DOI )

  3. Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, Tsuji K, Ohashi N, Yoshimura K, Nomura W, Mitsuya H, Maeda K, Tamamura H. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS infectious diseases. 2024.06; 10 (6): 2250-2261. ( PubMed, DOI )

  4. Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, Ishii T, Miura Y, Nishimura S, Shinohara K, Yamamoto K, Bolah P, Kotani O, Murakami T, Sato H, Tamamura H. Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins. Chemical & pharmaceutical bulletin. 2024; 72 (1): 41-47. ( PubMed, DOI )

  5. Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, Nomura W, Furuta T, Tamamura H. Effect of Two-Photon Excitation to 8-Azacoumarin Derivatives as Photolabile Protecting Groups. Chemical & pharmaceutical bulletin. 2024; 72 (3): 311-312. ( PubMed, DOI )

  6. Tsuji K, Tamamura H, Burke TR Jr. Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3. Biological & pharmaceutical bulletin. 2024; 47 (7): 1282-1287. ( PubMed, DOI )

  7. Kohei Tsuji, Takuya Kobayakawa, Takahiro Ishii, Nobuyo Higashi-Kuwata, Chika Azuma, Kouki Shinohara, Yutaro Miura, Kenichi Yamamoto, Soshi Nishimura, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura. Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement. Chemical and Pharmaceutical Bulletin. 2023.12; 71 (12): 879-886. ( PubMed, DOI )

  8. Takuya Kobayakawa, Masayuki Amano, Miyuki Nakayama, Kohei Tsuji, Takahiro Ishii, Yutaro Miura, Kouki Shinohara, Kenichi Yamamoto, Masao Matsuoka, Hirokazu Tamamura. Development of anti-HBV agents targeting HBV capsid proteins. RSC Medicinal Chemistry. 2023.10; 14 (10): 1973-1980. ( PubMed, DOI )

  9. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Kouki Shinohara, Chika Azuma, Yutaro Miura, Hiroki Nakano, Naoya Wada, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura. Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties. Journal of Medicinal Chemistry. 2023.10; 66 (19): 13516-13529. ( PubMed, DOI )

  10. Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kohei Tsuji, Nami Ohashi, Shingo Nakahata, Airi Noborio, Kazuhisa Yoshimura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity. European Journal of Medicinal Chemistry. 2023.08; 256 115449. ( PubMed, DOI )

  11. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Yutaro Miura, Takahiro Ishii, Kouki Shinohara, Takuya Kobayakawa, Akino Emi, Takashi Nakano, Youichi Suzuki, Hirokazu Tamamura . Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2 RSC Advances. 2023.03; 13 8779-8793.

  12. Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai, Hiromi Ogata-Aoki, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Nobutoki Takamune, Naoki Kishimoto, Shin-Ichiro Hattori, Debananda Das, Yukari Uemura, Yosuke Shimizu, Manabu Aoki, Kazuya Hasegawa, Satoshi Suzuki, Akie Nishiyama, Junji Saruwatari, Yukiko Shimizu, Yoshikazu Sukenaga, Yuki Takamatsu, Kiyoto Tsuchiya, Kenji Maeda, Kazuhisa Yoshimura, Shun Iida, Seiya Ozono, Tadaki Suzuki, Tadashi Okamura, Shogo Misumi, Yoshihiro Kawaoka, Hirokazu Tamamura, Hiroaki Mitsuya. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023.02; 14 (1): 1076. ( PubMed, DOI )

  13. Kanako Matsuura, Mizuki Yamaura, Hiromi Sakawaki, Ai Himeno, Yalcin Pisil, Takuya Kobayakawa, Kohei Tsuji, Hirokazu Tamamura, Shuzo Matsushita, Tomoyuki Miura. Sensitivity to a CD4 mimic of a consensus clone of monkey-adapted CCR5-tropic SHIV-MK38C. Virology. 2023.01; 578 171-179. ( PubMed, DOI )

  14. Rongyi Wang, Kohei Tsuji, Takuya Kobayakawa, Yishan Liu, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors Bioorganic & Medicinal Chemistry. 2022.12; 76 117083. ( PubMed, DOI )

  15. Kaho Matsumoto, Takeo Kuwata, William D Tolbert , Jonathan Richard, Shilei Ding, Jérémie Prévost, Shokichi Takahama, George P Judicate, Takamasa Ueno, Hirotomo Nakata, Takuya Kobayakawa, Kohei Tsuji , Hirokazu Tamamura, Amos B Smith 3rd, Marzena Pazgier, Andrés Finzi, Shuzo Matsushita. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates. Journal of virology. 2022.12; 97 (1): e0163822. ( PubMed, DOI )

  16. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Chika Azuma, Miyuki Nakayama, Takato Onishi, Hiroki Nakano, Naoya Wada, Miki Hori, Kouki Shinohara, Yutaro Miura, Takuma Kawada, Hironori Hayashi, Shin-Ichiro Hattori, Haydar Bulut, Debananda Das, Nobutoki Takamune, Naoki Kishimoto, Junji Saruwatari, Tadashi Okamura, Kenta Nakano, Shogo Misumi, Hiroaki Mitsuya, Hirokazu Tamamura. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022.11; 105365. ( PubMed, DOI )

  17. Kohei Tsuji, David Hymel, Buyong Ma, Hirokazu Tamamura, Ruth Nussinov, Terrence R Burke Jr. Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1. RSC chemical biology. 2022.08; 3 (9): 1111-1120. ( PubMed, DOI )

  18. Kohei Tsuji, Takuya Kobayakawa, Kiju Konno, Ami Masuda, Kohei Takahashi, Nami Ohashi, Kazuhisa Yoshimura, Takeo Kuwata, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors. Bioorganic & Medicinal Chemistry. 2022.02; 56 116616. ( PubMed, DOI )

  19. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nami Ohashi, Wataru Nomura & Hirokazu Tamamura. Fluorescence resonance energy transfer-based screening for protein kinase C ligands using 6-methoxynaphthalene-labeled 1,2-diacylglycerol-lactones. Organic & Biomolecular Chemistry. 2021.10; 19 (38): 8264-8271. ( PubMed, DOI )

  20. David Hymel, Kohei Tsuji, Robert A Grant, Ramesh M Chingle, Dominique L Kunciw, Michael B Yaffe, Terrence R Burke Jr. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles. Organic & Biomolecular Chemistry. 2021.09; 19 (36): 7843-7854. ( PubMed, DOI )

  21. Takuya Kobayakawa, Chika Azuma, Yuki Watanabe, Shunsuke Sawamura, Atsuhiko Taniguchi, Yoshio Hayashi, Kohei Tsuji & Hirokazu Tamamura. Development of Methods for Convergent Synthesis of Chloroalkene Dipeptide Isosteres and Its Application. The Journal of Organic Chemistry. 2021.03; 86 (7): 5091-5101. ( PubMed, DOI )

  22. Matsuda Kouki, Kobayakawa Takuya, Kariya Ryusho, Tsuchiya Kiyoto, Ryu Shoraku, Tsuji Kohei, Ishii Takahiro, Gatanaga Hiroyuki, Yoshimura Kazuhisa, Okada Seiji, Hamada Akinobu, Mitsuya Hiroaki, Tamamura Hirokazu, Maeda Kenji. A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators FRONTIERS IN MICROBIOLOGY. 2021.03; 12 636276. ( PubMed, DOI )

  23. Takuya Kobayakawa, Masaru Yokoyama, Kohei Tsuji, Masayuki Fujino, Masaki Kurakami, Sayaka Boku, Miyuki Nakayama, Moemi Kaneko, Nami Ohashi, Osamu Kotani, Tsutomu Murakami, Hironori Sato & Hirokazu Tamamura. Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins. Biomolecules. 2021.02; 11 (2): 208. ( PubMed, DOI )

  24. Takuya Kobayakawa, Kohei Tsuji, Kiju Konno, Ai Himeno, Ami Masuda, Tingting Yang, Kohei Takahashi, Yusuke Ishida, Nami Ohashi, Takeo Kuwata, Kaho Matsumoto, Kazuhisa Yoshimura, Hiromi Sakawaki, Tomoyuki Miura, Shigeyoshi Harada, Shuzo Matsushita & Hirokazu Tamamura. Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors. Journal of Medicinal Chemistry. 2021.01; 64 (3): 1481-1496. ( PubMed, DOI )

  25. Kohei Tsuji, Rongyi Wang, Takuya Kobayakawa, Kofi Baffour-Awuah Owusu, Masayuki Fujino, Moemi Kaneko, Naoki Yamamoto, Tsutomu Murakami, Hirokazu Tamamura. Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment. Bioorganic & Medicinal Chemistry. 2021.01; 30 115923. ( PubMed, DOI )

  26. Takuya Kobayakawa, Kento Ebihara, Kohei Tsuji, Takuma Kawada, Masayuki Fujino, Yuzuna Honda, Nami Ohashi, Tsutomu Murakami, Hirokazu Tamamura. Bivalent HIV-1 fusion inhibitors based on peptidomimetics. Bioorg. Med. Chem. 2020.12; 28 (24): 115812. ( PubMed, DOI )

  27. Stephen E. Miller, Kohei Tsuji, Rachel P.M. Abrams, Terrence R. Burke, Jr., Joel P. Schneider. Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions. J. Am. Chem. Soc. 2020.11; 142 (47): 19950-19955. ( PubMed, DOI )

  28. Kohei Tsuji, David Hymel, Terrence R. Burke, Jr.. A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. Anal. Methods: advancing methods and applications. 2020.09; 12 (36): 4418-4421. ( PubMed, DOI )

  29. Junpeng Qi, Kohei Tsuji, David Hymel, Terrence R. Burke, Jr., Michael Hudecek, Christoph Rader, Haiyong Peng. Chemically Programmable and Switchable CAR-T Therapy Angew. Chem., Int. Ed. 2020.07; 59 (29): 12178-12185 . ( PubMed, DOI )

  30. Tsuji Kohei, Owusu Kofi Baffour-Awuah, Kobayakawa Takuya, Wang Rongyi, Fujino Masayuki, Kaneko Moemi, Yamamoto Naoki, Murakami Tsutomu, Tamamura Hirokazu. Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment BIOORGANIC & MEDICINAL CHEMISTRY. 2020.06; 28 (11): 115488. ( PubMed, DOI )

  31. Kobayakawa T, Takano H, Ishii T, Tsuji K, Ohashi N, Nomura W, Furuta T, Tamamura H. Synthesis of hydrophilic caged DAG-lactones for chemical biology applications. Organic & biomolecular chemistry. 2020.06; 18 (22): 4217-4223. ( PubMed, DOI )

  32. Hwang D, Tsuji K, Park H, Burke TR Jr, Rader C. Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. Bioconjugate chemistry. 2019.11; 30 (11): 2889-2896. ( PubMed, DOI )

  33. Kawahara Haruka, Miyashita Naoki, Tachibana Koki, Tsuda Yusuke, Morimoto Kyohei, Tsuji Kohei, Shigenaga Akira, Otaka Akira, Ishida Tatsuhiro, Okuhira Keiichiro. A Photo-Activatable Peptide Mimicking Functions of Apolipoprotein A-I BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2019.06; 42 (6): 1019-1024.

  34. Zhao XZ, Tsuji K, Hymel D, Burke TR Jr. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules (Basel, Switzerland). 2019.04; 24 (8): 1488. ( PubMed, DOI )

  35. Hogan M, Bahta M, Tsuji K, Nguyen TX, Cherry S, Lountos GT, Tropea JE, Zhao BM, Zhao XZ, Waugh DS, Burke TR Jr, Ulrich RG. Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds. ACS combinatorial science. 2019.03; 21 (3): 158-170. ( PubMed, DOI )

  36. Hymel D, Grant RA, Tsuji K, Yaffe MB, Burke TR Jr. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorganic & medicinal chemistry letters. 2018.10; 28 (19): 3202-3205. ( PubMed, DOI )

  37. Tanegashima Kosuke, Takahashi Rena, Nuriya Hideko, Iwase Rina, Naruse Naoto, Tsuji Kohei, Shigenaga Akira, Otaka Akira, Hara Takahiko. CXCL14 Acts as a Specific Carrier of CpG DNA into Dendritic Cells and Activates Toll-like Receptor 9-mediated Adaptive Immunity EBIOMEDICINE. 2017.10; 24 247-256. ( PubMed, DOI )

  38. Mitsuhiro Eto, Naoto Naruse, Kyohei Morimoto, Kosuke Yamaoka, Kohei Sato, Kohei Tsuji, Tsubasa Inokuma, Akira Shigenaga, Akira Otaka. Development of an Anilide-Type Scaffold for the Thioester Precursor N-Sulfanylethylcoumarinyl Amide. Org. Lett.. 2016.08; 18 (17): 4416-4419. ( PubMed, DOI )

  39. Kohei Tsuji, Kosuke Tanegashima, Kohei Sato, Ken Sakamoto, Akira Shigenaga, Tsubasa Inokuma, Takahiko Hara, Akira Otaka. Efficient one-pot synthesis of CXCL14 and its derivative using an N-sulfanylethylanilide peptide as a peptide thioester equivalent and their biological evaluation. Bioorg. Med. Chem.. 2015.09; 23 (17): 5909-5914. ( PubMed, DOI )

  40. Chiharu Mizuguchi, Fuka Ogata, Shiho Mikawa, Kohei Tsuji, Teruhiko Baba, Akira Shigenaga, Toshinori Shimanouchi, Keiichiro Okuhira, Akira Otaka, Hiroyuki Saito. Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes. J. Biol. Chem.. 2015.08; 290 (34): 20947-20959. ( PubMed, DOI )

  41. Yusuke Tsuda, Akira Shigenaga, Kohei Tsuji, Masaya Denda, Kohei Sato, Keisuke Kitakaze, Takahiro Nakamura, Tsubasa Inokuma, Kohji Itoh, Akira Otaka. Development of a Chemical Methodology for the Preparation of Peptide Thioesters Applicable to Naturally Occurring Peptides Using a Sequential Quadruple Acyl Transfer System. ChemistryOpen. 2015.08; 4 (4): 448-452. ( PubMed, DOI )

  42. Yuki Takechi-Haraya, Kento Tanaka, Kohei Tsuji, Yasuo Asami, Hironori Izawa, Akira Shigenaga, Akira Otaka, Hiroyuki Saito, Kohsaku Kawakami. Molecular complex composed of β-cyclodextrin-grafted Chitosan and pH-sensitive amphipathic peptide for enhancing cellular cholesterol efflux under acidic pH. Bioconjug. Chem.. 2015.03; 26 (3): 572-581. ( PubMed, DOI )

  43. Emi Adachi, Asako Kosaka, Kohei Tsuji, Chiharu Mizuguchi, Hiroyuki Kawashima, Akira Shigenaga, Kohjiro Nagao, Kenichi Akaji, Akira Otaka, Hiroyuki Saito. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett.. 2014.01; 588 (3): 389-394. ( PubMed, DOI )

  44. Kosuke Tanegashima#, Kohei Tsuji#, Kenji Suzuki, Akira Shigenaga, Akira Otaka, Takahiko Hara (#Equally contributed). Dimeric peptides of the C-terminal region of CXCL14 function as CXCL12 inhibitors. FEBS Lett.. 2013.11; 587 (23): 3770-3775. ( PubMed, DOI )

  45. Kosuke Tanegashima, Kenji Suzuki, Yuki Nakayama, Kohei Tsuji, Akira Shigenaga, Akira Otaka, Takahiko Hara. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett.. 2013.06; 587 (12): 1731-1735. ( PubMed, DOI )

  46. Ken Sakamoto, Kohei Sato, Akira Shigenaga, Kohei Tsuji, Shugo Tsuda, Hajime Hibino, Yuji Nishiuchi, Akira Otaka. Synthetic procedure for N-Fmoc amino acyl-N-sulfanylethylaniline linker as crypto-peptide thioester precursor with application to native chemical ligation. J. Org. Chem.. 2012.08; 77 (16): 6948-6958. ( PubMed, DOI )

  47. Kohei Sato, Akira Shigenaga, Kohei Tsuji, Shugo Tsuda, Yoshitake Sumikawa, Ken Sakamoto, Akira Otaka. N-sulfanylethylanilide peptide as a crypto-thioester peptide. Chembiochem. 2011.08; 12 (12): 1840-1844. ( PubMed, DOI )

  48. Kohei Tsuji, Akira Shigenaga, Yoshitake Sumikawa, Kosuke Tanegashima, Kohei Sato, Keisuke Aihara, Takahiko Hara, Akira Otaka. Application of N-C- or C-N-directed sequential native chemical ligation to the preparation of CXCL14 analogs and their biological evaluation. Bioorg. Med. Chem.. 2011.07; 19 (13): 4014-4020. ( PubMed, DOI )

▼display all

Conference Activities & Talks 【 display / non-display

  1. 山本 賢一、小早川 拓也、東 知佳、渡邉 優基、辻 耕平、玉村 啓和. アミロイドbeta凝集阻害剤を指向したクロロアルケン型ペプチドミメティックの創製. 日本薬学会第144回年会 2024.03.31 横浜

  2. 黒田 悠貴, 小早川 拓也, 辻 耕平, 紺野 奇重, 大橋 南美, 増田 亜美, 三浦 裕太郎, 桑田 岳夫, 吉村 和久, 三浦 智行, 原田 恵嘉, 松下 修三, 玉村 啓和. HIV侵入阻害剤としてのポリエチレングリコールと低分子CD4ミミックのハイブリッド化合物の創製. 日本薬学会第144回年会 2024.03.30 横浜

  3. 町田 沙穂, 小早川 拓也, 横山 勝, 藤野 真之, 金子 萌美, 倉上 真樹, 朴 清香, 大西 立人, 小谷 治, 辻 耕平, 村上 努, 佐藤 裕徳, 玉村 啓和. HIV-1カプシドタンパク質の構造を起点とした低分子型抗HIV-1剤の創製. 日本薬学会第144回年会 2024.03.30 横浜

  4. 西村 壮史, 小早川 拓也, 辻 耕平, 村上 努, 玉村 啓和. HIV-1外被タンパク質gp41を標的とする二価型膜融合阻害剤の創製. 日本薬学会第144回年会 2024.03.30 横浜

  5. 篠原 功紀,鍬田 伸好,辻 耕平,石井 貴大,小早川 拓也,服部 真一朗,岸本 直樹,高宗 暢暁,三隅 将吾,Haydar Bulut,林 宏典,満屋 裕明,玉村 啓和. SARS-CoV-2メインプロテアーゼを標的とした高抗ウイルス活性を有する低分子阻害剤の創製. 日本薬学会第144回年会 2024.03.30 横浜

  6. Takuya Kobayakawa, Chika Azuma, Kenichi Yamamoto, Kohei Tsuji, Hirokazu Tamamura. Development of synthetic strategies for peptidomimetic based on a chloroalkene dipeptide isostere and its application to a cyclic peptide. The 15th International Kyoto Conference on New Aspects of Organic Chemistry 2023.11.21 Kyoto

  7. Kohei Tsuji, Hirokazu Tamamura, Terrence R. Burke, Jr.. Utilization of a non-specific kinase inhibitor for the development of high-affinity bivalent polo-like kinase 1 polo-box domain inhibitors. The 60th Japanese Peptide Symposium 2023.11.10 Otsu

  8. Takuya Kobayakawa, Chika Azuma, Kenichi Yamamoto, Kohei Tsuji, Hirokazu Tamamura. Development of convergent synthesis for peptidomimetic based on a chloroalkene dipeptide isostere and its application to a cyclic peptide. The 60th Japanese Peptide Symposium 2023.11.08 Otsu

  9. Kouki Shinohara, Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Yutaro Miura, Chika Azuma, Hironori Hayashi, Shin-ichiro Hattori, Haydar Bulut, Shogo Misumi, Hiroaki Mitsuya, Hirokazu Tamamura. Structure-activity relationship studies of novel SARS-CoV-2 main protease inhibitors with potent antiviral activity. The 60th Japanese Peptide Symposium 2023.11.08 Otsu

  10. Yutaro Miura, Rongyi Wang, Kohei Tsuji, Yishan Liu, Takuya Kobayakawa, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Combinational use of CD4 mimic with other anti-HIV agents and development of these hybrid molecules. 14th International Peptide Symposium 2023.10.17 Brisbane

  11. Yutaro Miura, Rongyi Wang, Kohei Tsuji, Yishan Liu, Takuya Kobayakawa, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Double target inhibitors of HIV-1 entry based on hybrid molecules of CD4 mimics and HIV-1 gp41-related peptides. 26th Korean Peptide Protein Symposium 2023.07.04 Jeju

  12. Takahiro Ishii, Kohei Tsuji, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Chika Azuma, Kouki Shinohara, Yutaro Miura, Hironori Hayashi, Haydar Bulut, Shogo Misumi, Hiroaki Mitsuya, Hirokazu Tamamura . Design and Synthesis of SARS-CoV-2 Mpro Inhibitors Containing Flurine Atoms and Amide Surrogates. 26th KPPS Annual Symposium 2023.07.03 Jeju

  13. Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kohei Tsuji, Nami Ohashi, Kazuhisa Yoshimura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura . Structure-Activity Relationship Studies of DAG-lactone Derivatives with HIV-1 Latancy Reversing Activity. 14th AFMC International Medicinal Chemistry Symposium 2023.06.27 Seoul

  14. Yutaro Miura, Rongyi Wang, Kohei Tsuji, Yishan Liu, Takuya Kobayakawa, Kazuhisa Yoshimura, Shuzo Matsushita, Shigeyoshi Harada, Hirokazu Tamamura. Hybrid molecules of CD4 mimic and HIV-1 fusion inhibitors. 14th AFMC International Medicinal Chemistry Symposium 2023.06.26 Seoul

  15. Kohei Tsuji, Kofi Baffour-Awuah Owusu, Takuya Kobayakawa, Youichi Suzuki, Hirokazu Tamamura. Development of fusion inhibitor peptides of SARS-CoV-2 learned from anti-HIV-1 agents. 第59回ペプチド討論会 2022.10.26 仙台

  16. Kouki Shinohara, Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Yutaro Miura, Hironori Hayashi, Shin-ichiro Hattori, Haydar Bulut, Shogo Misumi, Hiroaki Mitsuya, Hirokazu Tamamura. Structure-activity relationship studies of SARS-CoV-2 main protease inhibitors. 第59回ペプチド討論会 2022.10.26 仙台

  17. Yutaro Miura, Takuya Kobayakawa, Kohei Tsuji, Kiju Konno, Ami Masuda, Nami Ohashi, Takeo Kuwata, Kazuhisa Yoshimura, Tomoyuki Miura, Shigeyoshi Harada, Shuzo Matsushita, Hirokazu Tamamura. Pegylated CD4 mimics as HIV inhibitors. 第59回ペプチド討論会 2022.10.26 仙台

  18. Takahiro Ishii, Kohei Tsuji, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Chika Azuma, Miyuki Nakayama, Kouki Shinohara, Yutaro Miura, Hironori Hayashi, Shin-ichiro Hattori, Haydar Bulut, Shogo Misumi, Hiroaki Mitsuya, Hirokazu Tamamura. Synthesis of inhibitors targeting the main protease of SARS-CoV-2 for therapeutics of COVID-19. 第59回ペプチド討論会 2022.10.26 仙台

  19. Kohei Tsuji, Rongyi Wang, Kofi Baffour-Awuah Owusu, Takuya Kobayakawa, Tsutomu Murakami, Hirokazu Tamamura. Exploration of novel class anti-HIV-1 agents derived from a viral capsid protein. 36th European and 12th International Peptide Symposium 2022.08.29 Spain

  20. 石井 貴大, 小早川 拓也, 松田 幸樹, 辻 耕平, 吉村 和久, 満屋 裕明, 前田 賢次, 玉村 啓和. HIV 感染症の根治を指向した DAG-ラクトン誘導体の構造最適化研究. 日本ケミカルバイオロジー学会 第16回年会 2022.05.31 富山

  21. 石井 貴大, 小早川 拓也, 松田 幸樹, 辻 耕平, 吉村 和久, 満屋 裕明, 前田 賢次, 玉村 啓和. HIV感染症の根治を指向したDAG-ラクトン誘導体の合成. 日本薬学会第142年会 2022.03.27 online

  22. Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nami Ohashi, Wataru Nomura, Hirokazu Tamamura. A FRET-BASED ASSAY SYSTEM FOR PROTEIN KINASE C LIGAND SCREENING USING 1,2-DIACYLGLYCEROL-LACTONE DERIVATIVE. 第58回ペプチド討論会 2021.10.20 online(Tokyo)

  23. Kohei Tsuji. Kinase inhibitors for anti-cancer drugs. The 7th Joint Symposium between Chulalongkorn University and IBB/TMDU on Biomedical Materials and Engineering 2020.12.22 online (Thailand)

  24. Kohei Tsuji, David Hyme, Buyong Ma, Ruth Nussinov, Hirokazu Tamamura,Terrence R. Burke, Jr.. Development of bivalent inhibitors of polo-like kinase 1 with great affinity enhancement. 第57回ペプチド討論会 2020.11.10 online

  25. Kofi Baffour-Awuah Owusu, Kohei Tsuji, Rongyi Wang, Takuya Kobayakawa, Moemi Kaneko, Tsutomu Murakami, Hirokazu Tamamura. Exploratory studies on the development of anti-HIV-1 peptides based on HIV-1 capsid fragments. 第57回ペプチド討論会 2020.11.10 online

  26. Chika Azuma, Takuya Kobayakawa, Kohei Tsuji, Hirokazu Tamamura. A convergent synthesis of chloroalkene dipeptide isosteres as peptidomimetics. 第57回ペプチド討論会 2020.11.09 online

▼display all

Awards & Honors 【 display / non-display

  • Research Award for Young Scientists, Kanto branch of the Pharmaceutical Society of Japan,The Pharmaceutical Society of Japan Kanto Branch,2024.07

Others 【 display / non-display

  • Expanding the arsenal of drugs against COVID-19,2022.12